Continued from page 2

Until it shows wider promise, enthusiasm will be tepid, said Dr. Elizabeth Plimack a prostate specialist at the Fox Chase Cancer Center in Philadelphia.

“I’ve not had any patient ask for it,” she said. “They ask about it. Based on the information, they think the cost is tremendous, and they think the benefit is very small.”

Logothetis, at M.D. Anderson, said Provenge and other experimental cancer vaccines in development need “a national investment” to sort out their potential, starting with Medicare coverage.

“It’s no longer a fringe science. This is working,” he said. “We need to get it in the door so we can evolve it.”



Where to get help:



_Patient Advocate Foundation, 800-532-5274

_CancerCare, 866-552-6729

_Chronic Disease Fund, 877-968-7233

_Healthwell Foundation, 800-675-8416

_Leukemia & Lymphoma Society, 877-557-2672

_National Organization for Rare Disorders 800-999-6673

Story Continues →